*Actual product packaging may differ from the image shown.
CJC / Ipamorelin
CJC-1295 / Ipamorelin is a synergistic growth hormone–supporting peptide combination designed to stimulate the body’s natural growth hormone release in a smooth, physiologic way. CJC-1295 extends the signaling of growth hormone–releasing hormone (GHRH), while Ipamorelin stimulates growth hormone pulses without significantly increasing cortisol or prolactin. Together, this combination supports healthy growth hormone patterns, lean muscle development, fat metabolism, recovery, and overall vitality—without the use of exogenous growth hormone.
Protocols developed under the clinical direction of Dr. Jonathann Kuo, MD
Select Size:
What happens after checkout
- ①Purchase your treatment
- ②Complete your Qualiphy consultation via email (~3 min)
- ③Licensed provider reviews & approves your prescription
- ④Pharmacy ships within 3–5 days of approval
After checkout, you'll receive an email to complete your telehealth consultation. A licensed provider must approve before your order ships.
Potential benefits may include:
- Stimulates natural growth hormone release and pulsatility
- Supports lean muscle growth and preservation
- Promotes fat metabolism and improved body composition
- Enhances recovery from exercise, injury, or stress
- Supports deeper, more restorative sleep
- May improve energy levels, endurance, and overall vitality
- Complements resistance training, recovery protocols, and longevity-focused therapies
- Pregnancy or Breastfeeding: Safety has not been established; use is not recommended.
- Active Cancer or Recent Cancer Treatment: Growth hormone–pathway peptides are generally avoided.
- Known Allergy: Avoid use if you have a sensitivity to peptide-based therapies or formulation components.
- Endocrine or pituitary disorders, Severe Liver or Kidney Disease: Use with provider guidance to ensure appropriate dosing and monitoring.
CJC-1295 / Ipamorelin is generally well tolerated when used under medical supervision. Mild, short-term effects may occasionally occur, especially when first starting or adjusting dose, including:
- Temporary redness, tenderness, or itching at the injection site
- Mild headache or light fatigue as growth hormone signaling adjusts
- Temporary water retention or mild bloating
- Increased hunger, particularly early in therapy
- Vivid dreams or changes in sleep patterns (often a sign of GH activity)
These effects are typically mild and resolve as the body adapts. Provider check ins and regular bloodwork is recommended to monitor IGF-1 levels.
For safe and informed use, review the Extension Health Injection Reaction Guide (PDF), which outlines what to expect, how to reduce discomfort, and when to seek medical support.
- Weeks 1–2: CJC-1295 and Ipamorelin begin stimulating the body’s natural growth hormone pulses in a physiologic, balanced way. Early effects are primarily hormonal and cellular rather than visible. Some patients notice subtle improvements in sleep quality, recovery, or overall sense of well-being during this phase.
- Weeks 3–6: As growth hormone signaling becomes more consistent, the body becomes more efficient at fat metabolism, muscle repair, and tissue recovery. Patients may begin to notice gradual improvements in energy, exercise recovery, sleep depth, and body composition—especially when paired with resistance training and adequate protein intake.
- Weeks 8–12: Sustained use supports ongoing growth hormone activity, improved body composition, and enhanced recovery capacity. Visible changes in lean muscle tone, fat distribution, sleep quality, and overall vitality are more likely during this phase. Results tend to be steady and cumulative, making CJC-1295 / Ipamorelin well suited for long-term optimization, performance support, and healthy aging rather than rapid transformation.